Krishna Institute of Medical Sciences (KIMS) Q4 25/26 earnings summary

Executive summary

• Achieved 25% CAGR in revenue and 13% CAGR in EBITDA over the past three years, reflecting strong operational excellence and strategic expansion.

• Audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, were approved, with unmodified audit opinions issued by statutory auditors.

• FY26 operating revenue grew 28.6% year-over-year to ₹39,046 million, with total revenue at ₹39,308 million.

• Bed capacity expanded to 6,464 in FY26, with operations across Telangana, Andhra Pradesh, Maharashtra, Kerala, and Karnataka.

• Continued leadership in organ transplantation, neurosciences, and joint replacement programs.

Financial highlights

• FY26 consolidated revenue was ₹39,046 million, up from ₹30,351 million year-over-year; standalone revenue was ₹17,015 million.

• FY26 EBITDA rose to ₹8,282 million, up 1.6% year-over-year; EBITDA margin declined to 21.1% from 26.6% in FY25.

• PAT for FY26 was ₹2,420 million, down 41.7% year-over-year; PAT margin dropped to 6.2%.

• Basic and diluted EPS for FY26 were ₹6.03, a 37.3% decrease year-over-year; standalone EPS was ₹6.52.

• One-time exceptional items included a ₹32 million (standalone) and ₹74 million (consolidated) increase in employee benefit provisions due to new labor codes.

Outlook and guidance

• Adding 1,300+ beds through greenfield projects, acquisitions, and O&M opportunities to drive future growth.

• Focus on regional market leadership and strategic doctor partnerships to accelerate new business growth.

• The company continues to monitor regulatory developments regarding labor codes and will adjust accounting treatment as needed.